Payment overview · 2025
General Payments
$88.08
6 reported records · 4 companies
Healthcare provider profile · identity verified
John Vincent Maylock, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GREENWOOD, SC · NPI 1366413833
Verified facts
What the public records show
CMS Open Payments records show John Vincent Maylock, M.D. received $88.08 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 46.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.00 | 46.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.14 | 18.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.09 | 18.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.85 | 16.9% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $88.08 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.85 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
121 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 690 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 559 | 148 |
| Lisinopril | Lisinopril | 368 | 95 |
| Losartan Potassium | Losartan Potassium | 326 | 94 |
| Metformin Hcl | Metformin Hcl | 295 | 82 |
| Gabapentin | Gabapentin | 275 | 86 |
| Omeprazole | Omeprazole | 262 | 75 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 55 |
| Furosemide | Furosemide | 176 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 48 |
| Simvastatin | Simvastatin | 161 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 58 |
| Metoprolol Tartrate | Metoprolol Tartrate | 137 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 40 |
| Januvia | Sitagliptin Phosphate | 128 | 35 |
| Montelukast Sodium | Montelukast Sodium | 121 | 39 |
| Ozempic | Semaglutide | 121 | 28 |
| Trazodone Hcl | Trazodone Hcl | 121 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 112 | 38 |
| Potassium Chloride | Potassium Chloride | 107 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 105 | 29 |
| Glipizide | Glipizide | 104 | 37 |
| Meloxicam | Meloxicam | 100 | 38 |
| Ezetimibe | Ezetimibe | 99 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 24 |
| Carvedilol | Carvedilol | 88 | 28 |
| Eliquis | Apixaban | 88 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 87 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 14 |
| Jardiance | Empagliflozin | 75 | 19 |
| Sertraline Hcl | Sertraline Hcl | 74 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 27 |
| Valsartan | Valsartan | 72 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 19 |
| Clonidine Hcl | Clonidine Hcl | 69 | 22 |
| Nifedipine Er | Nifedipine | 63 | 18 |
| Allopurinol | Allopurinol | 59 | 20 |
| Alprazolam | Alprazolam | 59 | 14 |
| Tramadol Hcl | Tramadol Hcl | 59 | 16 |
| Xarelto | Rivaroxaban | 59 | suppressed |
| Celecoxib | Celecoxib | 57 | 17 |
| Spironolactone | Spironolactone | 56 | 16 |
| Buspirone Hcl | Buspirone Hcl | 55 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 55 | 17 |
| Pregabalin | Pregabalin | 55 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 55 | 11 |
| Ibuprofen | Ibuprofen | 54 | 26 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 54 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 52 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 22 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 11 |
| Famotidine | Famotidine | 47 | 14 |
| Meclizine Hcl | Meclizine Hcl | 47 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 46 | 36 |
| Atenolol | Atenolol | 45 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 20 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 12 |
| Farxiga | Dapagliflozin Propanediol | 42 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 21 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Prednisone | Prednisone | 37 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | 11 |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Linzess | Linaclotide | 31 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | 11 |
| Diclofenac Potassium | Diclofenac Potassium | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 24 | 24 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Levemir Flexpen | Insulin Detemir | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 14 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Fluconazole | Fluconazole | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 12 |
| Sildenafil Citrate | Sildenafil Citrate | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 14 |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 11 |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lovastatin | Lovastatin | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Unithroid | Levothyroxine Sodium | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $88.08 · 6 records | Novo Nordisk Inc | Cologuard Collection Kit, OTEZLA, REPATHA, VOQUEZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error